Innovation Pharmaceuticals (Innovation Pharmaceuticals) EBITDA Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Innovation Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Innovation Pharmaceuticals's EBITDA for the three months ended in Sep. 2023 was $-0.77 Mil. Innovation Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Innovation Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2023 was 0.00%.

Innovation Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Innovation Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation Pharmaceuticals EBITDA Margin % Chart

Innovation Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBITDA Margin %

Get a 7-Day Free Trial

-1,421.99

-36,355.56

Innovation Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Innovation Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Innovation Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovation Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Innovation Pharmaceuticals's EBITDA Margin % falls into.

Innovation Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Innovation Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-2.738	/	0
	=	%

Innovation Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.772	/	0
	=	%

Innovation Pharmaceuticals (OTCPK:IPIX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Innovation Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Innovation Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovation Pharmaceuticals (Innovation Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovation Pharmaceuticals Inc (OTCPK:IPIX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880

Website

http://www.ipharminc.com

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

Executives

Arthur Peter Bertolino	officer: Pres. & Chief Medical Officer	C/O INNOVATION PHARMACEUTICALS INC., 100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Jane A. Harness	officer: Vice President	100 CUMMINGS CENTER, SUITE 151-B, BEVERLY MA 01915
Mark Robert Tobin	director	C/O LIGHTBRIDGE CORPORATION, 11710 PLAZA AMERICA DRIVE, SUITE 2000, RESTON VA 20190
Zorik Spektor	director	17615 FIELDBROOK CIRCLE E, BOCA RATON FL 33496
Barry A Schechter	director	7814 TENNYSON CT., BOCA RATON FL 33433
Leo Ehrlich	director, 10 percent owner, officer: Chief Financial Officer	C/O INNOVATION PHARMACEUTICALS INC., 301 EDGEWATER PLACE - SUITE 100, WAKEFIELD MA 01880
Krishna Menon	director, 10 percent owner, officer: President-Chief Scient.Officer	10 BRIDLE WAY, NORTH READING MA 01864
George W. Evans	director, officer: Chief Executive Officer	17 IRVING PLACE, PELHAM NY 10803